会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • GENETIC POLYMORPHISMS SENSITIVELY PREDICTING ADVERSE DRUG REACTIONS (ADR) AND DRUG EFFICACY
    • 遗传多态性敏感预测不良药物反应(ADR)和药物效能
    • WO2004018708A3
    • 2004-08-26
    • PCT/EP0308298
    • 2003-07-28
    • BAYER HEALTHCARE AGSCHWERS STEPHANKALLABIS HARALDREIFENBERGER ELKESTROPP UDOSCHMITZ GERD
    • SCHWERS STEPHANKALLABIS HARALDREIFENBERGER ELKESTROPP UDOSCHMITZ GERD
    • C12Q1/68
    • C12Q1/6883C12Q2600/156
    • The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-21 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.
    • 本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒,包括确定人类受试者在他汀类药物治疗后是否有患上药物反应风险的抗体或人类受试者是高反应者还是低反应者 他汀类药物或代谢物。 本发明提供了进一步的诊断方法和试剂盒,包括确定人受试者是否处于心血管疾病风险的抗体。 本发明进一步涉及编码表型相关(PA)基因多肽的分离的多核苷酸,其用于鉴定治疗剂并可用于制备治疗心血管疾病或影响药物反应的药物的方法 所述多核苷酸选自如SEQ ID 1-21所示的组,其具有等位基因变异,如包含在功能性周围的序列部分中所示,如PA基因多肽的全长cDNA并具有或不具有PA基因启动子序列。
    • 6. 发明申请
    • METHOD FOR THE ANALYSIS OF EXOGENIC AND ENDOGENIC CELL ACTIVATION
    • 法分析外源性和内源性细胞活化
    • WO0165257A3
    • 2002-03-28
    • PCT/DE0100817
    • 2001-03-05
    • SCHMITZ GERDGOETZ ALEXANDRA
    • SCHMITZ GERDGOETZ ALEXANDRA
    • G01N33/542G01N33/566G01N33/569A61K31/00A61K38/00A61K39/00
    • G01N33/566G01N33/542G01N33/56972G01N2400/50
    • The invention relates to a method for the analysis of exogenic and endogenic cell activation, comprising the measurement of the aggregation of receptors in a CD14-inclusive receptor cluster. The above is preferably achieved, by the measurement of the energy transfer between the individual receptors, whereby a measurement by means of fluorescence resonance energy transfer (FRET) is preferred. The invention further relates to a method for the diagnosis of systemic inflammations, such as sepsis, arteritis, or auto-immune disease states, or an arteriosclerotic or inflammatory disease of the coronary arteries (CAD such as angina pectoris, coronary infarct or coronary scleroses), or of the cerebral arteries (such as stroke), or a pre-cursor to one of these disease states, which is based on a measurement of the aggregation of receptors in a CD14-inclusive receptor cluster and, furthermore, the use of compounds which inhibit the clustering of CD14 for treatment of the above disease states.
    • 本发明涉及一种方法,用于分析外源性和内源性细胞的活化,包括在包含受体簇一个CD14受体组装的测量。 优选地,这是通过测量所述个体的受体,由此通过荧光共振能量转移的装置(FRET)的测定是优选的之间的能量转移来完成。 本发明还涉及一种方法,用于诊断全身性炎症例如脓毒症,动脉炎或自身免疫性疾病,或动脉硬化或冠状动脉(CAD,如心绞痛,心肌梗塞或Coronarsclerosen)或脑动脉(如中风)的炎性疾病或的前体 的这些疾病,这是基于组装受体在CD14受体,包括簇,以及使用该防止CD14的聚类对这些疾病的治疗的化合物的测量值。